<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989531</url>
  </required_header>
  <id_info>
    <org_study_id>Accost</org_study_id>
    <nct_id>NCT03989531</nct_id>
  </id_info>
  <brief_title>Adrecizumab in Cardiogenic Shock</brief_title>
  <acronym>ACCOST-HH</acronym>
  <official_title>Investigator-initiated, Placebo-controlled, Double-blind, Multi-center, Randomized Trial to Assess the Efficacy and Safety of Adrecizumab in Subjects With Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Mahir Karakas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiogenic shock is a serious medical condition with high mortality and morbidity. This
      trial assesses safety, tolerability and efficacy of Adrecizumab on top of standard of care in
      patients with cardiogenic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite optimal treatment the mortality in patients with cardiogenic shock still exceeds 50%
      and surviving patients mostly suffer from severe heart failure due to an impaired cardiac
      function.It is hypothesized, that Adrenomedullin is a key player in the (dys)-regulation of
      vascular integrity. Adrecizumab is the first-in-class humanized monoclonal
      anti-Adrenomedullin antibody, and acts as a long-lasting plasma Adrenomedullin enhancer
      stabilizing barrier function at a reasonable safety profile.When the anti-Adrenomedullin
      antibody Adrecizumab is administered in the blood circulation at high concentrations by far
      exceeding those of plasma Adrenomedullin, the compartmental distribution of Adrenomedullin is
      altered. Adrecizumab, an IgG with a molecular weight of more than 150 kDa, is too large to
      freely diffuse from the blood circulation to the interstitium. With its fast association
      kinetics Adrecizumab quickly binds to Adrenomedullin in the blood circulation and &quot;pulls&quot;
      Adrenomedullin, which has been initially located in the interstitium, from this compartment
      to the blood circulation. The more Adrecizumab is applied, the stronger is the &quot;pulling&quot;
      effect and the higher the resulting concentrations of Adrecizumab-bound Adrenomedullin in the
      blood circulation. The increase of Adrecizumab-bound Adrenomedullin in the blood circulation
      occurs within 5-15 minutes after administration of Adrecizumab, since it induces a
      translocation of preformed Adrenomedullin. As a consequence of this redistribution, the
      Adrenomedullin concentration in the interstitium decreases, and less Adrenomedullin is able
      to act on smooth muscle cells to exert its vasodilatative activity. In the progression to
      cardiogenic shock, when it comes to excessive vasodilation and hypotension, administration of
      Adrecizumab thus can reduce vasodilation by substracting excessive levels of interstitially
      located Adrenomedullin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need of cardiovascular organ support within the first 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days through day 30 without need for cardiovascular organ support, including vasopressors, or mechanical support (VA-ECMO, Impella)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day-Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Adrecizumab on top of standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo on top of standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mL saline as single dose infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adrecizumab</intervention_name>
    <description>Drip infusion over 60 minutes</description>
    <arm_group_label>Adrecizumab on top of standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drip infusion over 60 minutes</description>
    <arm_group_label>Placebo on top of standard of care</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Hospitalization for Cardiogenic shock (at the discretion of the local investigator)

        Cardiogenic shock is usually defined as:

          -  Systolic blood pressure &lt; 90 mmHg &gt; 30 min or inotropes required to maintain pressure
             &gt; 90 mmHg during systole

          -  Signs of left heart insufficiency and/ or pulmonary congestion

          -  Signs of impaired organ perfusion with at least one of the following:

          -  Altered mental status

          -  Cold, clammy skin

          -  Urine output &lt;30 ml/h

          -  Serum lactate &gt;2mmol/l

               -  Age above 18 years at time of screening

               -  Body weight below 150 kg at time of screening

               -  Females/Males who agree to comply with the applicable contraceptive requirements
                  of the protocol

        Exclusion Criteria:

          -  Cardiogenic shock due to significant arrhythmias, which include any of the following:
             sustained ventricular tachycardia, bradycardia with sustained ventricular rate &lt;35
             beats per minute, or atrial fibrillation/ flutter with sustained ventricular response
             of &gt;160 beats per minute

          -  Cardiogenic shock due to left ventricular outflow obstruction, obstructive
             hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area &lt;0.8
             cm2 or mean gradient &gt;50 mmHg on prior or current echocardiogram), and severe mitral
             stenosis

          -  Cardiogenic shock due to mechanical cause or severe bleeding

          -  Cardiogenic shock due to untreated clinically significant CAD requiring
             revascularization

          -  Resuscitation &gt; 60 minutes

          -  Severe pre-existing hepatic disease unrelated to cardiogenic shock

          -  Severe pre-existing renal disease (dialysis) unrelated to cardiogenic shock etiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir Karakas, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahir Karakas, MD, MBA</last_name>
    <phone>+4915222817493</phone>
    <email>m.karakas@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Berlin, Campus Benjamin-Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carsten Skurk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahir Karakas, MD, MBA</last_name>
      <phone>+4915222817493</phone>
      <email>m.karakas@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjam Kessler, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Dr. med. Mahir Karakas</investigator_full_name>
    <investigator_title>PD Dr Mahir Karakas, MBA</investigator_title>
  </responsible_party>
  <keyword>Cardiogenic Shock</keyword>
  <keyword>Adrecizumab</keyword>
  <keyword>Vascular integrity</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

